Incidence of Side Efect Quinine in Malaria Patients in Bontang Public Hospital, East Kalimantan

  • NITA RISTIAWATI POLITEKNIK KESEHATAN KEMENKES

Abstract

Quinine intravenous for severe malaria and complications, is recommended until the patient is able to use the oral formulation. The purpose of this study was to monitor the side effects that arise during the administration of quinine in malaria patients in Bontang Public Hospital and evaluate the use of other drugs that may increase the incidence of quinine side effects. This study was conducted by using descriptive study design. Monitoring of side effects is based on qualitative data, through clinical observation before and after the patients received the drug. The events of side effects were evaluated from the data collectedby usingNaranjo algorithm to determine possible (score 1-4), probable (score 5-8) and certainty (definite) (score 9). From the study, it is found that 32 patients (88.89 %) experienced quinine side effects, 2 patients (5.55 %) did not experience significant side effects. 7 patients (19.44 %) were using cimetidin, 6 patients (16.67 %) had more than 2 side effects. Possible influence of cimetidine on the clearance of quinine that cause the increase of quinine levels in the blood may increase the risk of the events of quinine side effects.

References

1. Sungkar S, Pribadi W. Malaria. Jakarta: Balai Penerbit FKUI; 1994. 67-87.
2. Harijanto IRS. Malaria epidemiologi, patogenesis, manifestasi klinis & penanganan. Jakarta: EGC; 2000. 119-275.
3. Tjitra E. Obat antimalaria. Dalam:Hariyanto PN. Malaria epidemiologi, patogenesis, manifestasi klinis & penanganan. Ed. 1. Jakarta: EGC; 2000. 194-223.
4. WHO. Guidelines for the treatment of malaria. Geneva: WHO; 2006.
5. Okitolonda W, Delacolette C, Malengrean M, Henquin C. High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria. Br Med J. 1987. 19: 716-18.
6. WHO. Susceptibility of Plasmodium falciparum to antimalarial drug report for global monitoring. 1996-2004. Geneva: WHO; 2005.
7. American Society of Health-System Pharmacist. ASHP Guidelines on adverse drug reaction monitoring and reporting. Am J Health-Syst Pharm. 1995. 52: 417-9. 8. Bates DW. Clinical pharmacology basic principles in therapeutics. 4th Ed. New York: Mc Graw-Hill; 2000. 24-5.
9. Edwards IR. Drug benefits and risks international text book of clinical pharmacology. New York: John Wiley & Sons.Ltd; 2001.135-274.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981.30: 239-245.
11. Oberg KC. Adverse drug reactions. Am J Pharm Educ. 1999.63:199-204.
12. Roche RJ, Silamut K, Pukriitayakamee S, Looreesuwan S, Molunto P, Boonamrung S, White NJ. Quinine induces reversible high-tone hearing loss. Br J Clin Pharmac. 1990.29:780-2.
13. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med. 1982. 73:564-71.
14. White NJ, Looareesuwan S, Warrell DA. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg.1983.32:1-5.
15. Silamut K, White NJ, Warrell DA, Looareesuwan S. Binding of quinine to plasma proteins in falciparum malaria. Am J Trop Hyg. 1985.34: 681-6.
16. Bunnag D, Karbwang J, Na Bangchang K, Thanabul A, Chittamas S, Harinasuta T. Quinine- tetracycline for multidrug resistant falciparum malaria in South East Asian. J Trop Med Public Health. 1996. 27:15-8.
17. Parola P, Rangue S, Badiaga S, Niang M, Blin O, Charbit J, Delmont J, Brouqul P. Controlled trial of 3-day quinine clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother. 2001(45): 923-35.
18. Bruce-Chwatt LJ.Essential malariology. Geneva: London School of Hygiene and Tropica Medicine; 1981. 174-203.
19. Sompon W, Sunbhanichi M, Pongmarutail M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J clin Pharmac. 1986. (22): 346-50.
20. Tatro DS. Drug interaction facts. 5th Ed. St. Louis: Facts and Comparison; 2001.
21. Stockley IH. Stockley’s drug interactions. Nottingham: University of Nottingham Medical School; 2002.765-6.
Published
2015-04-30
How to Cite
RISTIAWATI, NITA. Incidence of Side Efect Quinine in Malaria Patients in Bontang Public Hospital, East Kalimantan. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 13, n. 1, p. 56-62, apr. 2015. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/125>. Date accessed: 23 nov. 2024.
Citation Formats
Issue
Vol 13 No 1 (2015): JIFI
Section
Articles
License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.